Objective: In France, terminations of pregnancy (TOP) for medical reasons beyond the second trimester use mifepristone and misoprostol. We sought to determine the effectiveness of Dilapan-S®, an osmotic cervical dilator, in shortening the induction-to-delivery interval (IDI). Materials and Methods: This retrospective study of TOP in 2010-2012 compared the results from 2 hospitals with different TOP protocols starting at 16 weeks' gestation, one (164 women) with and one (106) without Dilapan-S®. The principal endpoint was the IDI. Results were analyzed according to 2 definitions of induction onset: definition 1, first dose of misoprostol in both centers, or definition 2, dilator placement if used, and otherwise first dose of misoprostol. Results: With definition 1, the IDI was shorter with dilators (5 h 48 min vs. 10 h 18 min, p < 0.001); the rates of uterine evacuation within 12 and 24 h were higher (94.5 and 100 vs. 68.9 and 91.5%, p < 0.001), and the time between first misoprostol dose and amniotomy was shorter (0 h 47 min vs. 4 h 30 min, p < 0.001). Under definition 2, the IDI was longer with dilators (18 h 24 min vs. 10 h 18 min, p < 0.001), but the rate of evacuation within 24 h did not differ significantly. Conclusion: Dilapan-S® acts on cervical ripening and dilatation, thereby allowing early amniotomy. Assessing potential side effects and women's satisfaction requires prospective trials.

Keywords:
Termination of pregnancy, Feticide, Mifepristone, Misoprostol, Second trimester, Third trimester, Dilators, Dilapan-S®
2.
Houfflin-Debarge V, Vaast P: Interruption médicale de grossesse. Processus décisionnel et prise en charge. Extrait des Mises à jour en Gynécologie et Obstétrique, Tome XXXII, publié le 3/12/2008, p 41.
3.
Hern WM: Laminaria versus Dilapan osmotic cervical dilators for outpatient dilation and evacuation abortion: randomized cohort comparison of 1001 patients. Am J Obstet Gynecol 1994;171:1324-1328.
4.
Darney PD: Preparation of the cervix: hydrophilic and prostaglandin dilators. Clin Obstet Gynaecol 1986;13:43-51.
5.
Perrotte F, Mirlesse V, De Vigan C, Kieffer F, Meunier E, Daffos F: Interruption médicale de grossesse pour anomalie foetale: le point de vue des patientes. J Gynecol Obstet Biol Reprod 2000;29:185-191.
6.
Burnett MA, Corbett CA, Gertenstein RJ: A randomized trial of laminaria tents versus vaginal misoprostol for cervical ripening in first trimester surgical abortion. J Obstet Gynaecol Can 2005;27:38-42.
7.
MacIsaac L, Grossman D, Balistreri E, Darney P: A randomized controlled trial of laminaria, oral misoprostol, and vaginal misoprostol before abortion. Obstet Gynecol 1999;93:766-770.
8.
Schaub B: Les protocoles en vigueur dans les CPDPN à l'heure de la mise en question du Cytotec hors AMM, présentation orale au Club de Médecine Foetale, 2013. Accessible at www.cpdpn.fr.
9.
Dodd JM, Crowther CA: Misoprostol for induction of labour to terminate pregnancy in the second or third trimester for women with a fetal anomaly or after intrauterine fetal death. Cochrane Database Syst Rev 2010;4: CD004901.
10.
Brouns JF, van Wely M, Burger MP, van Wijngaarden WJ: Comparison of two dose regimens of misoprostol for second-trimester pregnancy termination. Contraception 2010;82:266-275.
11.
Mandelbrot L, Girard G: Aspects techniques des interruptions médicales de grossesse. Extrait des Mises à jour en Gynécologie et Obstétrique, Tome XXXII, publié le 3/12/2008, p 7.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.